-
(2018)
References 1. Beers D, Appel S
-
Koji
Takei,
Kikumi
Tsuda,
Fumihiro
Takahashi,
M.
Hirai,
J.
Palumbo
(2017)
An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18
-
M.
Aoki
(2017)
Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18
-
M.
Cudkowicz,
J.
Shefner,
Elizabeth
Simpson,
D.
Grasso,
Hong
Yu,
Hui
Zhang,
A.
Shui,
D.
Schoenfeld,
Robert
Brown,
S.
Wieland,
J.
Barber
(2008)
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis
Muscle & Nerve, 38
-
Sarah
Milliken,
Heather
Wassall,
B.
Lewis,
Judith
Logie,
R.
Barker,
H.
Macdonald,
M.
Vickers,
A.
Ormerod
(2012)
Effects of ultraviolet light on human serum 25-hydroxyvitamin D and systemic immune function.
The Journal of allergy and clinical immunology, 129 6
-
K.
Abe,
M.
Aoki,
S.
Tsuji,
Y.
Itoyama,
G.
Sobue,
Masanori
Togo,
C.
Hamada,
Masahiko
Tanaka,
M.
Akimoto,
Kazue
Nakamura,
Fumihiro
Takahashi,
K.
Kondo,
H.
Yoshino,
H.
Sasaki,
I.
Yabe,
S.
Doi,
H.
Warita,
Takashi
Imai,
Hiroaki
Ito,
M.
Fukuchi,
E.
Osumi,
M.
Wada,
I.
Nakano,
M.
Morita,
K.
Ogata,
Y.
Maruki,
Kimiko
Ito,
O.
Kano,
M.
Yamazaki,
Yuji
Takahashi,
H.
Ishiura,
M.
Ogino,
R.
Koike,
C.
Ishida,
T.
Uchiyama,
K.
Mizoguchi,
T.
Obi,
Hirohisa
Watanabe,
N.
Atsuta,
I.
Aiba,
A.
Taniguchi,
H.
Sawada,
T.
Hazama,
H.
Fujimura,
H.
Kusaka,
T.
Kunieda,
H.
Kikuchi,
Hidenori
Matsuo,
H.
Ueyama,
K.
Uekawa,
Masaki
Ueda,
Aiko
Murakami,
Rie
Sumii,
Taku
Kudou,
K.
Morimoto,
Takatomo
Yoneoka,
M.
Hirai,
K.
Sasaki,
H.
Terai,
Tomoko
Natori,
H.
Matsui,
Kuniko
Kotani,
Kaori
Yoshida,
T.
Iwasaki
(2017)
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
The Lancet Neurology, 16
-
Koji
Takei,
Fumihiro
Takahashi,
Shawn
Liu,
Kikumi
Tsuda,
J.
Palumbo
(2017)
Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18
-
Albert
Taylor,
Christina
Fournier,
M.
Polak,
Liuxia
Wang,
N.
Zach,
Mike
Keymer,
J.
Glass,
D.
Ennist
(2016)
Predicting disease progression in amyotrophic lateral sclerosis
Annals of Clinical and Translational Neurology, 3
-
L.
Richardson
(2018)
The Writing Group
-
Shaoping
Wu,
Jianxun
Yi,
Yongguo
Zhang,
Jingsong
Zhou,
Jun
Sun
(2015)
Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model
Physiological Reports, 3
-
Rebecca
Sheean,
F.
McKay,
E.
Cretney,
C.
Bye,
Nirma
Perera,
D.
Tomas,
Richard
Weston,
Karlene
Scheller,
E.
Djouma,
P.
Menon,
S.
Schibeci,
N.
Marmash,
J.
Yerbury,
S.
Nutt,
D.
Booth,
G.
Stewart,
M.
Kiernan,
S.
Vucic,
B.
Turner
(2018)
Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model
JAMA Neurology, 75
-
J.
Friedman
(2001)
Greedy function approximation: A gradient boosting machine.
Annals of Statistics, 29
-
D.
Beers,
S.
Appel
(2019)
Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies
The Lancet Neurology, 18
-
M.
Benatar,
J.
Wuu,
P.
Andersen,
N.
Atassi,
W.
David,
M.
Cudkowicz,
D.
Schoenfeld
(2018)
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS
Neurology, 90
-
R.
Küffner,
N.
Zach,
R.
Norel,
Johann
Hawe,
D.
Schoenfeld,
Liuxia
Wang,
Guang
Li,
Li-shu
Fang,
Lester
Mackey,
O.
Hardiman,
M.
Cudkowicz,
A.
Sherman,
G.
Ertaylan,
M.
Grosse-Wentrup,
T.
Hothorn,
Jules
Ligtenberg,
J.
Macke,
Timm
Meyer,
B.
Scholkopf,
Linh
Tran,
Rubio
Vaughan,
G.
Stolovitzky,
Melanie
Leitner
(2014)
Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression
Nature Biotechnology, 33
-
J.
Berry,
Albert
Taylor,
Danielle
Beaulieu,
L.
Meng,
A.
Bian,
Jinsy
Andrews,
Mike
Keymer,
D.
Ennist,
B.
Ravina
(2018)
Improved stratification of ALS clinical trials using predicted survival
Annals of Clinical and Translational Neurology, 5
-
(2017)
Reference 1. Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group
-
(2017)
Amyotroph Lat Scler Frontotemporal Degener
-
Antonio
Elia,
S.
Lalli,
M.
Monsurrò,
A.
Sagnelli,
A.
Taiello,
B.
Reggiori,
V.
Bella,
G.
Tedeschi,
Alberto
Albanese
(2015)
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
European Journal of Neurology, 23
-
C.
Karam,
M.
Barrett,
T.
Imperato,
D.
Macgowan,
S.
Scelsa
(2013)
Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis
Journal of Clinical Neuroscience, 20
-
(2000)
Manual for the Beck Depression Inventory -Fast Screen for Medical Patients
-
L.
Berg,
E.
Sorenson,
G.
Gronseth,
E.
Macklin,
Jinsy
Andrews,
R.
Baloh,
M.
Benatar,
J.
Berry,
A.
Chiò,
P.
Corcia,
A.
Genge,
A.
Gubitz,
C.
Lomen‐Hoerth,
C.
Mcdermott,
E.
Pioro,
J.
Rosenfeld,
V.
Silani,
M.
Turner,
Markus
Weber,
B.
Brooks,
Robert
Miller,
H.
Mitsumoto
(2019)
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
Neurology, 92